A retrospective analysis revealed improved survival rates in laryngeal cancer patients who had postoperative wound infection following total laryngectomy and radical neck resection. The overall five-year survival rates were 44% in the infection group and 31% in the control group. On further analysis, the beneficial effect of infection was most evident in patients with stage III disease. Seventy-three percent of these patients with wound infection were alive at five years, compared with 32% of the control group.
The protection from recurrent cancer in these patients afforded by the bacterial contamination may be secondary to activated immune mechanisms. The therapeutic implications of our findings suggest that the immune adjuvant is given at the time of surgical treatment rather than when tumor burden is far advanced. Only a few such protocols are under analysis presently.
Get full access to this article
View all access options for this article.
References
1.
ColeyWB: Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci131:375–430, 1906.
2.
MillerTRNicholsonJT: End results in reticulum cell sarcoma of bone treated by bacterial toxin therapy alone or combined with surgery. Cancer27:524–548, 1971.
3.
OldLJBoyseEA: Current enigmas in cancer research. Harvey Lect67:273–315, 1972.
4.
OettgenHF: Immunotherapy of cancer. N Engl J Med297:484–491, 1977.
5.
LiebowitzALaurenceHS: Target cell destruction by antigen stimulated human lymphocytes. Fed Proc28:630–634, 1969.
6.
SmithHGBastRCZbarB: Eradication of microscopic lymph node metastases after injecting living BCG adjuvant to the primary tumor, J Natl Cancer Inst55:1345–1352, 1975.
7.
MackanessGBLagrangePHIshibashiI: The modifying effect of BCG on the immunologic induction of T-cells. J Exp Med139:1540–1552, 1974.
8.
CarswellEAOldLJ: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA72:3666–3670, 1975.
9.
RuckdeschelJCCodishSDStranahanA: Postoperative empyema improves survival in lung cancer: Documentation and analysis of a natural experiment. N Engl J Med287:1013–1017, 1972.
10.
ShieldsTWHigginsGAKeehnRJ: Factors influencing survival after resection for bronchial carcinoma. J Thorac Cardiovasc Surg64:391–397, 1972.
11.
McKneallyMFMaverCMKauselHW: Intrapleural BCG immunostimulation in lung cancer. Lancet1:1003–1009, 1977.
12.
McKneallyMFMaverCMKauselHW: Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg72:333–338, 1976.
13.
SkolnikEMYeeKFWheatleyMA: Panel discussion on glottic tumors: V. Carcinoma of the laryngeal glottis therapy and end results. Laryngoscope85:1453–1466, 1975.
14.
JesseRH: Panel discussion on glottic tumors: I. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. Laryngoscope85:1424–1429, 1975.
15.
BertinoJRBostorBCapizziRL: The role of chemotherapy in the management of cancer of the head and neck: A review. Cancer36:752–758, 1975.
16.
TarpleyJLChretienPBAlexanderJC: High dose MTX as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. Am J Surg130:481–486, 1975.
17.
CockeEWWangCC: Cancer of the larynx: Selecting optimum treatment. CA26:194–200, 1976.
18.
LeRoux-RobertJ: Panel discussion on glottic tumors: IV. A statistical study of 620 laryngeal carcinomas of the glottic region personally operated upon more than five years ago. Laryngoscope85:1440–1452, 1975.
19.
WangCC: Treatment of glottic carcinoma by megavoltage radiation therapy and results. AJR120:157–163, 1974.
20.
SkolnikEMMartinLOWheatleyMA: Combined therapy in the management of laryngeal carcinoma. Can J Otolaryngol4:236–245, 1975.
21.
McKneallyMFMaverCMKauselHW: Intrapleural BCG immunostimulation in lung cancer. Lancet1:1003–1009, 1977.
22.
BlumingAZVogelCLZeiglerJL: Immunologic effects of BCG in malignant melanoma: Two modes of administration compared. Ann Intern Med76:405, 1972.
23.
MortonDLEilberFRHolmesEC: BCG immunotherapy of malignant melanoma. Ann Surg180:635–641, 1974.
24.
EilberFRTownsendCMJr.MortonDL: Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg132:476–479, 1976.
25.
SuenJYRichmanSPLivingstonRB: Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. Am J Surg134:474–478, 1977.
26.
DonaldsonRC: Chemoimmunotherapy for cancer of the head and neck. Am J Surg126:507–512, 1973.
27.
EilberFRMortonDLKetchamAS: Immunologic abnormalities in head and neck cancer. Am J Surg128:534–538, 1974.
28.
BerlingerNTGoodRA: Concomitant immunopathology with squamous cell carcinomas of the head and neck regions. Trans Am Acad Ophthalmol Otolaryngol82ORL–588–ORL–594, 1976.
29.
DeeganMJCoulthardLOWheatleyMA: A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck. Cancer Res37:4475–4481, 1977.
30.
WaneboHJJunMYStrongEW: T-cell deficiency in patients with squamous cell cancer of the head and neck. Am J Surg130:445–451, 1975.
31.
CheemaARHershEM: Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer28:851–855, 1971.
StewartCCPerezCA: Effect of irradiation on immune responses. Radiology118:201–210, 1976.
34.
TarpleyJLPotvinCChretienPB: Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy. Cancer35:638–644, 1975.
35.
TarpleyJLTwomeyPLCatalonaWJ: Suppression of cellular immunity by anesthesia and operation. J Surg Res22:195–201, 1977.
36.
RothJAGolubSHGrimmEA: Effect of operation on immune response in cancer patients: Sequential evaluation of in vitro lymphocyte function. Surgery79:46–51, 1976.
37.
Compendium of Tumor Immunotherapy Protocols: International Registry of Tumor Immunotherapy, National Cancer Institute, No. 6, September1978, pp 397–415.
